Group 1 - Intellia Therapeutics, Inc. (NASDAQ:NTLA) experienced a significant stock increase, reaching a new all-time high of $27.98, with a daily gain of 13.05% [1] - The company received a bullish sentiment from investment firms, with JMP Securities giving an "outperform" rating and a price target of $33, indicating a potential upside of 17.9% from its latest closing price [2] - Intellia's drug candidate, lonvo-Z, is projected to capture a 19% market share, translating to a market opportunity of $2.8 billion [3] Group 2 - Topline data for Intellia's drug candidate is expected in the first half of 2026, with a biologics license application (BLA) targeted for submission in the second half of 2026 [4] - If approved by the FDA, the launch of the drug is scheduled for the first half of 2027 [4]
Intellia (NTLA) Soars 13% to Fresh High